Search

Displaying results 5961 - 5970 of 10000 in total
  1. Drug

    NRP369

    go.drugbank.com/drugs/DB06384
    Experimental

    NRP369 is an oxycodone derivative under investigation for the treatment of pain (moderate to moderately severe). NRP369 was developed by New River Pharmaceuticals as a backup therapeutic to [NRP290].

  2. Drug

    Brasofensine

    go.drugbank.com/drugs/DB04857
    Experimental

    In November 2001, NeuroSearch confirmed that the drug's development was discontinued in favor of NS 2230. … Brasofensine is an orally administered dopamine reuptake inhibitor being developed for the treatment of Parkinson's Disease. Phase I/II trials for brasofensine have been completed in the U.K.

  3. Drug

    Lestaurtinib

    go.drugbank.com/drugs/DB06469
    Investigational

  4. Drug

    Atibuclimab

    go.drugbank.com/drugs/DB06546
    Investigational

    Atibuclimab (IC14) is a chimeric CD14 antibody investigated for the treatment of patients with severe sepsis.

  5. Drug

    Labetuzumab

    go.drugbank.com/drugs/DB05097
    Investigational

    It is used in radioimmunotherapy.

  6. Drug

    7-Nitroindazole

    go.drugbank.com/drugs/DB02207
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  7. Drug

    Serabelisib

    go.drugbank.com/drugs/DB14935
    Investigational

    of TAK-117 (MLN1117) in Healthy Participants). … Serabelisib is under investigation in clinical trial NCT02625259 (A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics

  8. Drug

    Eldelumab

    go.drugbank.com/drugs/DB06116
    Investigational

    MDX-1100, a fully human antibody that targets IP10 (also known as CXCL10), a chemokine expressed in association with multiple inflammatory disease indications, such as rheumatoid arthritis, inflammatory

  9. Drug

    (+)-Mefloquine

    go.drugbank.com/drugs/DB05636
    Investigational

    (+)-Mefloquine was under investigation in clinical trial NCT00931697 (Study to Investigate the Safety, Tolerability and Pharmacokinetics of AD 452 [(+)-Mefloquine] Compared With Racemic Mefloquine) to

  10. Drug

    Trefoil Factor 2

    go.drugbank.com/drugs/DB15750
    Experimental

    The peptides themselves are most abundant in mucous cells of the gastric mucosa with TFF2 being detected in mucous layers over the tissue. … They are expressed predominantly in gastric tissues with the source for them being predominantly stromal cells, although expression of TFF2 mRNA transcripts also occurs with tissue macrophages.